An international study co-led by UCLA found that an investigational targeted therapy significantly extended survival for pancreatic cancer patients, researchers said Sunday. The study found that patients who received the drug daraxonrasib lived a median of 13.2 months compared with 6.7 months for those who received investigator’s choice chemotherapy. That represented a 60% reduction in […]
